- Home
- BFRI vs INTS Comparison
BFRI vs INTS Comparison
Compare BFRI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- INTS
- Stock Information
- Founded
- BFRI 1997
- INTS 2012
- Country
- BFRI United States
- INTS United States
- Employees
- BFRI N/A
- INTS N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- INTS Health Care
- Exchange
- BFRI Nasdaq
- INTS Nasdaq
- Market Cap
- BFRI 7.5M
- INTS 8.0M
- IPO Year
- BFRI 2021
- INTS 2023
- Fundamental
- Price
- BFRI $0.88
- INTS $0.33
- Analyst Decision
- BFRI Strong Buy
- INTS Strong Buy
- Analyst Count
- BFRI 1
- INTS 3
- Target Price
- BFRI $2.75
- INTS $8.50
- AVG Volume (30 Days)
- BFRI 238.6K
- INTS 3.7M
- Earning Date
- BFRI 08-13-2025
- INTS 08-07-2025
- Dividend Yield
- BFRI N/A
- INTS N/A
- EPS Growth
- BFRI N/A
- INTS N/A
- EPS
- BFRI N/A
- INTS N/A
- Revenue
- BFRI $37,997,000.00
- INTS N/A
- Revenue This Year
- BFRI $11.75
- INTS N/A
- Revenue Next Year
- BFRI $17.09
- INTS N/A
- P/E Ratio
- BFRI N/A
- INTS N/A
- Revenue Growth
- BFRI 14.28
- INTS N/A
- 52 Week Low
- BFRI $0.54
- INTS $0.26
- 52 Week High
- BFRI $2.22
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- BFRI 72.09
- INTS 41.29
- Support Level
- BFRI $0.66
- INTS $0.26
- Resistance Level
- BFRI $0.91
- INTS $0.32
- Average True Range (ATR)
- BFRI 0.07
- INTS 0.03
- MACD
- BFRI 0.02
- INTS 0.02
- Stochastic Oscillator
- BFRI 80.56
- INTS 62.56
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.